Facial Balancing With Filler: What It Is and What It Costs

Facial balancing is a planning approach rather than a product.

The injector looks at the face as a whole — how the forehead, nose, lips, chin and jawline line up in profile — and plans several areas together instead of treating one complaint in isolation.

The products are the same fillers used for single-area treatment.

In the US, dermal fillers are regulated as medical device implants that FDA approves through premarket approval, and each product's approval names its own areas; FDA's list includes the nasolabial folds, cheeks, chin, lips and the back of the hands.

"Facial balancing" is not an FDA-defined indication, and our research found no primary source for the typical syringe counts or total cost of full-face filler plans.

What the evidence supports is the frame: such plans combine fillers approved area by area, and any part of a plan with no approval behind it — the nose, the forehead — is off-label.

Because every area keeps its own label, it helps to start from the products themselves.

Our dermal fillers guide explains how fillers are approved and how the main brands differ.

A balancing plan draws on areas where fillers hold approvals, and the approval follows the product, not the plan.

These are examples of FDA-approved products by area, with the year each indication was approved.

The single-area questions live on their own pages: cheek filler, chin filler and jawline filler each have a guide of their own.

Smile lines are another labeled stop: Restylane Defyne is approved for deep nasolabial folds and Restylane Refyne for moderate to severe wrinkles and folds, both since 2016.

The nose is the exception worth knowing.

No US filler has an FDA-approved indication for the nose — the use often marketed as a non-surgical rhinoplasty — nor for the forehead or the glabella, per FDA's PMA file as of October 2026.

FDA's consumer page, last updated in February 2024, lists those same areas as uses its approvals do not cover; it also lists the area around the eyes, even though specific products now hold approvals for under-eye hollows (see the table above).

When a plan adds the nose, that part is off-label.

The risk data line up with the label gap.

In a 2024 review of 365 published cases of vision loss after filler injection, the most common sites were the nose (40.6% of cases), the forehead (27.7%) and the glabella (19.0%), and 68.2% of cases reporting outcomes had no vision recovery.

Our research found no published answer for a full plan: no primary source gives typical syringe counts or total cost of "facial balancing" or full-face filler plans.

Nor did our research find a standard number of syringes per area — no label, professional body or peer-reviewed source we checked gives one.

What exists are trial medians and label maximums, each specific to one product and one area.

In the Restylane Kysse US pivotal trial (273 subjects randomized 2:1 against a control), the median volume for initial and touch-up treatment together was 0.90 mL in the upper lip and 0.80 mL in the lower lip, within a median total of 2.50 mL across all treated areas.

The same product's label caps a session at 3 mL for the lips, within 6 mL per patient per treatment.

Syringe size is not fixed either.

Revanesse's Versa, Versa+ and Lips+ are approved in 1.0 mL and 1.2 mL syringes, so "one syringe" does not always mean 1 mL.

The practical step is to ask any practice to itemize the plan — which product, in which area, in how many syringes — so that quotes describe the same work.

Our research found no published total for a multi-area plan — no primary source gives the total cost of full-face filler plans.

What can be named are single-product and single-area figures, each from a named source.

Allergan says Juvéderm treatment can range from $600 to $1,400 depending on the product and the provider.

ASPS lists average costs of $715 for hyaluronic acid fillers, $901 for non-hyaluronic acid fillers such as Radiesse, Sculptra and Bellafill, and $743 for lip augmentation with filler.

Those ASPS figures are average fees reported by ASPS member plastic surgeons — not med spa prices — and ASPS does not state the data year or say whether the average covers one syringe or one procedure.

ASPS names the cost drivers: the injector's expertise and qualifications, the type of procedure, the time and effort required, and the geographic location of the office.

A balancing plan combines several products and areas in one visit, so several of those drivers can apply at once.

ASPS also notes that health insurance does not cover dermal fillers.

FDA states that dermal fillers are approved for adults aged 22 or older, with each product label setting the exact age.

FDA also says filler safety is unknown during pregnancy and breastfeeding, in people under age 22, and in people prone to keloid or hypertrophic scarring, and that treatment should be delayed if the skin is inflamed or infected.

FDA says to tell the provider about bleeding disorders, severe allergies or anaphylaxis, and allergies to lidocaine, collagen, eggs, animal products or bacteria.

Product labels add their own exclusions.

The Juvéderm labels are contraindicated with a history of multiple severe allergies or anaphylaxis, allergy to lidocaine or to the gram-positive bacterial proteins used in the products, or prior allergic reactions to hyaluronic acid fillers.

Because a balancing plan combines products — sometimes with a neuromodulator in the same visit — FDA's caution applies: the safety of fillers combined with neuromodulators such as Botox, and of repeated use over a long period, has not been evaluated in controlled clinical studies.

Candidacy for any filler plan is a decision for a licensed provider who can examine the face and medical history; this page describes what the labels and FDA say, not advice for any one person.

FDA advises choosing a licensed health care provider with dermatology or plastic-surgery experience who is trained in filler injection, and says filler injection should be considered a medical procedure, not a cosmetic treatment.

The safety question is concrete for a multi-area plan.

FDA tells injectors to know the signs of intravascular injection, to keep an updated plan for treating it — on-site treatment and/or immediate referral — and to stop injecting at signs such as skin blanching, vision change, stroke signs or unusual pain.

Expert reviews add that prompt recognition and immediate hyaluronidase are the mainstay of treating HA-filler vascular occlusion, and recommend emergency preparedness, including a "filler crash cart" and an in-office action protocol. Dissolving filler with hyaluronidase is itself off-label: products such as Hylenex are FDA-approved only to aid fluid administration, increase the dispersion and absorption of other injected drugs, and for subcutaneous urography.

FDA also says no filler is approved for over-the-counter use, and that people should not inject themselves or buy filler online.